Alzheimer Disease, Cognitive Decline, Multiple Sclerosis, Neurodegenerative Diseases, Parkinson Disease Dementia
Conditions
Brief summary
VESPA 2.0 is based on an integrative and ecological approach used for the treatment of cognitive dysfunction in patients with MCI or other neurodegenerative disorders.
Detailed description
The goal of this study is to verify the effectiveness of the intensive-individual cognitive participation intervention (SCI-i) on the general cognitive functioning and specific cognitive functions of patients with mild or moderate cognitive decline affected by Alzheimer's dementia, Parkinson's and Multiple Sclerosis. Participants will be subjected to cognitive training (tasks on attention, memory, language, executive functions, and visual-spatial functions) through software. They will take place using virtual cameras and virtual reality (VR) viewers. All subjects will undergo follow-up evaluation.
Interventions
DEVICEVespa software
The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).
Sponsors
IRCCS Centro Neurolesi Bonino Pulejo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients diagnosed with Alzheimer Disease, Multiple Sclerosis, Parkinson Disease * Severity of mild to moderate cognitive impairment * Sign informed consent
Exclusion criteria
* Important comorbidities with psychiatric syndromes * Failure to sign the informed consent * Atypical parkinsonisms * Clinical conditions that involve vision-related problems.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Montreal cognitive assessment (MoCA) | up to 6 weeks | MoCA (Montreal Cognitive Assessment or The MoCA Test) was validated as a highly sensitive tool for early detection of mild cognitive impairment (MCI) It quickly and accurately assesses: Short term memory; Visuospatial abilities; Executive functions; Attention, concentration, and working memory; Language; Orientation to time and place Results : 26-30 points: No cognitive impairment 18-25 points: Mild cognitive impairment. 10-17 points: Moderate cognitive impairment. Fewer than 10 points: Severe cognitive impairment. |
Countries
Italy
Outcome results
None listed